The causative role and therapeutic potential of the kynurenine pathway in neurodegenerative disease

Journal of Molecular Medicine

Volumn 91, Issue 6, 2013, Pages 705-713

  Amaral, Marta ^a,b,c,d   Outeiro, Tiago F ^c,d,e   Scrutton, Nigel S ^b   Giorgini, Flaviano ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^d INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^e UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

Kynurenine 3 monooxygenase; Kynurenine pathway; Neurodegenerative disease

Indexed keywords

3 HYDROXYANTHRANILIC ACID; 3 HYDROXYANTHRANILIC ACID OXYGENASE; 3 HYDROXYKYNURENINE; 3,4 DIMETHOXY N [4 (3 NITROPHENYL) 2 THIAZOLYL]BENZENESULFONAMIDE; 3,4 DIMETHOXY N[4 (3 NITROPHENYL)THIAZOL 2 YL]BENZENESULFONAMIDE; ARYLFORMAMIDASE; FORMAMIDASE; HYDROLASE; INDOLEAMINE 2,3 DIOXYGENASE 1; INDOLEAMINE 2,3 DIOXYGENASE 2; KYNURENIC ACID; KYNURENIN 3 MONOOXYGENASE; KYNURENINASE; KYNURENINE; KYNURENINE AMINOTRANSFERASE; KYNURENINE INHIBITOR; NEUROPROTECTIVE AGENT; NICOTINAMIDE ADENINE DINUCLEOTIDE; QUINOLINATE PHOSPHORIBOSYL TRANSFERASE; QUINOLINIC ACID; TRYPTOPHAN 2,3 DIOXYGENASE; UNCLASSIFIED DRUG; UPF 648;

ALZHEIMER DISEASE; CRYSTALLOGRAPHY; DEGENERATIVE DISEASE; DRUG STRUCTURE; DRUG TARGETING; HUMAN; HUNTINGTON CHOREA; IC 50; METABOLITE; NEUROPROTECTION; NONHUMAN; PROTEIN DEGRADATION; REVIEW;

ANIMALS; HUMANS; KYNURENINE; KYNURENINE 3-MONOOXYGENASE; NEURODEGENERATIVE DISEASES;

EID: 84878618542     PISSN: 09462716     EISSN: 14321440     Source Type: Journal    
DOI: 10.1007/s00109-013-1046-9     Document Type: Review

References (96)

1. Thevandavakkam MA, Schwarcz R, Muchowski PJ, Giorgini F (2010) Targeting kynurenine 3-monooxygenase (KMO): implications for therapy in Huntington's disease. CNS Neurol Disord Drug Targets 9(6):791-800
2. Metz R, Duhadaway JB, Kamasani U, Laury-Kleintop L, Muller AJ, Prendergast GC (2007) Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res 67(15):7082-7087
3. Han Q, Cai T, Tagle D, Li J (2010) Structure, expression, and function of kynurenine aminotransferases in human and rodent brains. Cellular and molecular life sciences: CMLS 67(3):353-368
4. Schwarcz R, Bruno JP, Muchowski PJ, Wu HQ (2012) Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci 13(7):465-477
5. Ying W (2008) NAD+/NADH and NADP+/NADPH in cellular functions and cell death: regulation and biological consequences. Antioxid Redox Signal 10(2):179-206
6. Grohmann U (2003) Tolerance, DCs and tryptophan: much ado about IDO. Trends in Immunology 24(5):242-248
7. Frumento G, Rotondo R, Tonetti M, Damonte G, Benatti U, Ferrara GB (2002) Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J Exp Med 196(4):459-468
8. Katz JB, Muller AJ, Prendergast GC (2008) T-cell tolerance and tumoral immune escape. Immunol Rev 222:206-221
9. Pilotte L, Larrieu P, Stroobant V, Colau D, Dolusic E, Frédérick R, De Plaen E, Uyttenhove C, Wouters J, Masereel B et al (2012) Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase. Proc Natl Acad Sci U S A 109(7):2497-2502
10. Munn DH (2006) Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation. Curr Opin Immunol 18(2):220-225
11. Uyttenhove C, Pilotte L, Théate I, Stroobant V, Colau D, Parmentier N, Boon T, Van den Eynde B (2003) Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 9(10):1269-1274
12. Nguyen NT, Kimura A, Nakahama T, Chinen I, Masuda K, Nohara K, Fujii-Kuriyama Y, Kishimoto T (2010) Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism. Proc Natl Acad Sci U S A 107(46):19961-19966
13. Mezrich JD, Fechner JH, Zhang X, Johnson BP, Burlingham WJ, Bradfield CA (2010) An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J Immunol 185(6):3190-3198
14. Röhrig UF, Awad L, Grosdidier A, Larrieu P, Stroobant V, Colau D, Cerundolo V, Simpson AJ, Vogel P, Van den Eynde BJ et al (2010) Rational design of indoleamine 2,3-dioxygenase inhibitors. J Med Chem 53(3):1172-1189
15. Yue EW, Douty B, Wayland B, Bower M, Liu X, Leffet L, Wang Q, Bowman KJ, Hansbury MJ, Liu C et al (2009) Discovery of potent competitive inhibitors of indoleamine 2,3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model. J Med Chem 52(23):7364-7367
16. Opitz CA, Litzenburger UM, Sahm F, Ott M, Tritschler I, Trump S, Schumacher T, Jestaedt L, Schrenk D, Weller M et al (2011) An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 478(7368):197-203
17. Lapin IP (1978) Stimulant and convulsive effects of kynurenines injected into brain ventricles in mice. J Neural Transm 42(1):37-43
18. Stone TW, Perkins MN (1981) Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS. Eur J Pharmacol 72(4):411-412
19. Schwarcz R, Whetsell WO Jr, Mangano RM (1983) Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. Science 219(4582):316-318
20. Behan WM, McDonald M, Darlington LG, Stone TW (1999) Oxidative stress as a mechanism for quinolinic acid-induced hippocampal damage: protection by melatonin and deprenyl. Br J Pharm 128(8):1754-1760
21. Rios C, Santamaria A (1991) Quinolinic acid is a potent lipid peroxidant in rat brain homogenates. Neurochem Res 16(10):1139-1143
22. Whetsell WO, Schwarcz R (1989) Prolonged exposure to submicromolar concentrations of quinolinic acid causes excitotoxic damage in organotypic cultures of rat corticostriatal system. Neurosci Lett 97:271-275
23. Stone TW, Mackay GM, Forrest CM, Clark CJ, Darlington LG (2003) Tryptophan metabolites and brain disorders. Clin Chem Lab Med 41(7):852-859
24. Perkins MN, Stone TW (1982) An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid. Brain Research 247(1):184-187
25. Wang J, Simonavicius N, Wu X, Swaminath G, Reagan J, Tian H, Ling L (2006) Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35. J Biol Chem 281(31):22021-22028
26. Hilmas C, Pereira EF, Alkondon M, Rassoulpour A, Schwarcz R, Albuquerque EX (2001) The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. J Neurosci 21(19):7463-7473
27. Sapko MT, Guidetti P, Yu P, Tagle DA, Pellicciari R, Schwarcz R (2006) Endogenous kynurenate controls the vulnerability of striatal neurons to quinolinate: implications for Huntington's disease. Exp Neurol 197:31-40
28. Fukui S, Schwarcz R, Rapoport SI, Takada Y, Smith QR (1991) Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J Neurochem 56(6):2007-2017
29. Fulop F, Szatmari I, Vamos E, Zadori D, Toldi J, Vecsei L (2009) Syntheses, transformations and pharmaceutical applications of kynurenic acid derivatives. Curr Med Chem 16(16):4828-4842
30. Gellért L, Fuzik J, Göblös A, Sárközi K, Marosi M, Kis Z, Farkas T, Szatmári I, Fülöp F, Vécsei L et al (2011) Neuroprotection with a new kynurenic acid analog in the four-vessel occlusion model of ischemia. Eur J Pharmacol 667(1-3):182-187
31. Rossi F, Schwarcz R, Rizzi M (2008) Curiosity to kill the KAT (kynurenine aminotransferase): structural insights into brain kynurenic acid synthesis. Curr Opin Struct Biol 18(6):748-755
32. Vamos E, Pardutz A, Klivenyi P, Toldi J, Vecsei L (2009) The role of kynurenines in disorders of the central nervous system: possibilities for neuroprotection. J Neurol Sci 283(1-2):21-27
33. Okuda S, Nishiyama N, Saito H, Katsuki H (1996) Hydrogen peroxide-mediated neuronal cell death induced by an endogenous neurotoxin, 3-hydroxykynurenine. Proc Natl Acad Sci U S A 93(22):12553-12558
34. Okuda S, Nishiyama N, Saito H, Katsuki H (1998) 3-Hydroxykynurenine, an endogenous oxidative stress generator, causes neuronal cell death with apoptotic features and region selectivity. J Neurochem 70(1):299-307
35. Guillemin GJ, Kerr SJ, Smythe GA, Smith DG, Kapoor V, Armati PJ, Croitoru J, Brew BJ (2001) Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. J Neurochem 78(4):842-853
36. Guillemin GJ, Croitoru-Lamoury J, Dormont D, Armati PJ, Brew BJ (2003) Quinolinic acid upregulates chemokine production and chemokine receptor expression in astrocytes. Glia 41(4):371-381
37. Pearson SJ, Reynolds GP (1992) Increased brain concentrations of a neurotoxin, 3-hydroxykynurenine, in Huntington ' s disease. Neurosci Lett 144:199-201
38. Ogawa T, Matson W, Beal M, Myers R, Bird E, Milbury P, Saso S (1992) Kynurenine pathway abnormalities in Parkinson's disease. Neurology 42(9):1702-1706
39. Sardar A, Reynolds P (1995) Frontal cortex indoleamine-2,3-dioxygenase activity is increased in HIV-l-associated dementia. Neurosci Lett 187:9-12
40. Guidetti P, Schwarcz R (1999) 3-Hydroxykynurenine potentiates quinolinate but not NMDA toxicity in the rat striatum. Eur J Neurosci 11(11):3857-3863
41. Copeland CS, Neale SA, Salt TE (2013) Actions of xanthurenic acid, a putative endogenous group II metabotropic glutamate receptor agonist, on sensory transmission in the thalamus. Neuropharmacology 66:133-142
42. Fazio F, Lionetto L, Molinaro G, Bertrand HO, Acher F, Ngomba RT, Notartomaso S, Curini M, Rosati O, Scarselli P et al (2012) Cinnabarinic acid, an endogenous metabolite of the kynurenine pathway, activates type 4 metabotropic glutamate receptors. Mol Pharmacol 81(5):643-656
43. Ross CA, Tabrizi SJ (2011) Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol 10(1):83-98
44. Ho LW, Carmichael J, Swartz J, Wyttenbach A, Rankin J, Rubinsztein DC (2001) The molecular biology of Huntington's disease. Psychol Med 31(1):3-14
45. Guidetti P, Luthi-Carter RE, Augood SJ, Schwarcz R (2004) Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease. Neurobiol Dis 17(3):455-461
46. Guidetti P, Bates GP, Graham RK, Hayden MR, Leavitt BR, MacDonald ME, Slow EJ, Wheeler VC, Woodman B, Schwarcz R (2006) Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice. Neurobiol Dis 23(1):190-197
47. Giorgini F (2012) Targeting the kynurenine pathway in Huntington ' s disease. ACNR 12(1):7-8
48. Jauch D, Urbaiiska EM, Guidetti P, Bird ED, Vonsattel JG, Whetsell W, Schwartz R (1995) Dysfunction of brain kynurenic acid metabolism in Huntington's disease: focus on kynurenine aminotransferases. J Neurol Sci 130:39-47
49. Stoy N, Mackay GM, Forrest CM, Christofides J, Egerton M, Stone TW, Darlington LG (2005) Tryptophan metabolism and oxidative stress in patients with Huntington's disease. J Neurochem 93(3):611-623
50. Mazarei G, Neal SJ, Becanovic K, Luthi-Carter R, Simpson EM, Leavitt BR (2010) Expression analysis of novel striatal-enriched genes in Huntington disease. Hum Mol Genet 19(4):609-622
51. Orr AL, Li S, Wang C-E, Li H, Wang J, Rong J, Xu X, Mastroberardino PG, Greenamyre JT, Li X-J (2008) N-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking. J Neurosci 28(11):2783-2792
52. Bordelon YM, Chesselet MF, Nelson D, Welsh F, Erecińska M (1997) Energetic dysfunction in quinolinic acid-lesioned rat striatum. J Neurochem 69(4):1629-1639
53. Stone TW, Darlington LG (2002) Endogenous kynurenines as targets for drug discovery and development. Nat Rev Drug Discov 1(8):609-620
54. Okamoto H, Yamamoto S, Nozaki M, Hayaishi O (1967) On the submitochondrial localization of L-kynurenine-3-hydroxylase. Biochem Biophys Res Commun 26(3):309-314
55. John R, Truscott W (2007) Eye lens proteins and cataracts. Protein misfolding, aggregation and conformational diseases. pp 435-447
56. Korlimbinis A, Hains PG, Truscott RJ, Aquilina JA (2006) 3-Hydroxykynurenine oxidizes alpha-crystallin: potential role in cataractogenesis. Biochemistry 45(6):1852-1860
57. Giorgini F, Möller T, Kwan W, Zwilling D, Wacker JL, Hong S, Tsai LC, Cheah CS, Schwarcz R, Guidetti P et al (2008) Histone deacetylase inhibition modulates kynurenine pathway activation in yeast, microglia, and mice expressing a mutant huntingtin fragment. J Biol Chem 283(12):7390-7400
58. Campesan S, Green EW, Breda C, Sathyasaikumar KV, Muchowski PJ, Schwarcz R, Kyriacou CP, Giorgini F (2011) The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington's disease. Curr Biol 21(11):961-966
59. Sathyasaikumar KV, Stachowski EK, Amori L, Guidetti P, Muchowski PJ, Schwarcz R (2010) Dysfunctional kynurenine pathway metabolism in the R6/2 mouse model of Huntington's disease. J Neurochem 113(6):1416-1425
60. Citron M (2010) Alzheimer's disease: strategies for disease modification. Nat Rev Drug Discov 9(5):387-398
61. Rahman A, Ting K, Cullen KM, Braidy N, Brew BJ, Guillemin GJ (2009) The excitotoxin quinolinic acid induces tau phosphorylation in human neurons. PLoS One 4(7):1-15
62. Guillemin GJ, Smythe GA, Veas LA, Takikawa O, Brew BJ (2010) Ab1-42 induces production of quinolinic acid by human macrophages and microglia. Neuroreport 14(18):311-315
63. Guillemin GJ, Brew BJ, Noonan CE, Takikawa O, Cullen KM (2005) Indoleamine 2,3 dioxygenase and quinolinic acid immunoreactivity in Alzheimer's disease hippocampus. Neuropathol Appl Neurobiol 31(4):395-404
64. Hartai Z, Juhász A, Rimanóczy A, Janáky T, Donkó T, Dux L, Penke B, Tóth GK, Janka Z, Kálmán J (2007) Decreased serum and red blood cell kynurenic acid levels in Alzheimer's disease. Neurochem Int 50(2):308-313
65. Heyes MP, Saito K, Crowley JS, Davis LE, Demitrack M, Der M, Dilling L, Elia J, Kruesi MJ, Lackner A (1992) Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. Brain 115:1249-1273
66. Gulaj E, Pawlak K, Bien B, Pawlak D (2010) Kynurenine and its metabolites in Alzheimer's disease patients. Adv Med Sci 55(2):204-211
67. Bonda DJ, Mailankot M, Stone JG, Garrett MR, Castellani RJ, Siedlak SL, Zhu X, Perry G, Nagaraj RH, Smith MA (2011) Indoleamine 2,3-dioxygenase and 3OH-kynurenine modifications are found in the neuropathology of Alzheimer disease. Redox Rep 15(4):161-168
68. Baran H, Jellinger K, Deecke L (1999) Kynurenine metabolism in Alzheimer's disease. J Neural Transm 106(2):165-181
69. Giorgini F, Guidetti P, Nguyen Q, Bennett SC, Muchowski PJ (2006) A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington's disease. Nat Genet 37(5):526-531
70. Zwilling D, Huang SY, Sathyasaikumar KV, Notarangelo FM, Guidetti P, Wu HQ, Lee J, Truong J, Andrews-Zwilling Y, Hsieh EW et al (2011) Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell 145(6):863-874
71. Pellicciari R, Amori L, Costantino G, Giordani A, Macchiarulo A, Mattoli L, Pevarello P, Speciale C, Varasi M (2003) Modulation of the kynurenine pathway of tryptophan metabolism in search for neuroprotective agents. Focus on kynurenine-3-hydroxylase. Adv Exp Med Biol 527:621-628
72. Ceresoli-Borroni G, Guidetti P, Amori L, Pellicciari R, Schwarcz R (2007) Perinatal kynurenine 3-hydroxylase inhibition in rodents: pathophysiological implications. J Neurosci Res 85(4):845-854
73. Amori L, Guidetti P, Pellicciari R, Kajii Y, Schwarcz R (2009) On the relationship between the two branches of the kynurenine pathway in the rat brain in vivo. J Neurochem 109(2):316-325
74. Röver S, Cesuraa M, Huguenin P, Kettler R, Szente A (1997) Synthesis and biochemical evaluation of N-(4-phenylthiazol-2-yl)benzenesulfonamides as high-affinity inhibitors of kynurenine 3-hydroxylase. J Med Chem 40(26):4378-4385
75. Carpenedo R, Meli E, Peruginelli F, Pellegrini-Giampietro DE, Moroni F (2002) Kynurenine 3-mono-oxygenase inhibitors attenuate post-ischemic neuronal death in organotypic hippocampal slice cultures. J Neurochem 82(6):1465-1471
76. Grégoire L, Rassoulpour A, Guidetti P, Samadi P, Bédard PJ, Izzo E, Schwarcz R, Di Paolo T (2008) Prolonged kynurenine 3-hydroxylase inhibition reduces development of levodopa-induced dyskinesias in parkinsonian monkeys. Behav Brain Res 186(2):161-167
77. Amori L, Wu HQ, Marinozzi M, Pellicciari R, Guidetti P, Schwarcz R (2009) Specific inhibition of kynurenate synthesis enhances extracellular dopamine levels in the rodent striatum. Neuroscience 159(1):196-203
78. Green E, Campesan S, Breda C, Sathyasaikumar K, Muchowski P, Schwarcz R, Kyriacou C, Giorgini F (2012) Drosophila eye color mutants as therapeutic tools for Huntington disease. Fly 6(2):117-120
79. van der Goot AT, Zhu W, Vázquez-Manrique RP, Seinstra RI, Dettmer K, Michels H, Farina F, Krijnen J, Melki R, Buijsman RC et al (2012) Delaying aging and the aging-associated decline in protein homeostasis by inhibition of tryptophan degradation. Proc Nat Acad Sci U S A 109(37):14912-14917
80. Saito Y, Hayaishi O, Rothberg S (1957) Studies on oxygenases. Enzymatic formation of 3-hydroxy-L-kynurenine from L-kynurenine. J Biol Chem 2(229):921-934
81. Okamoto H, Hayaishi O (1967) Flavin adenine dinucleotide requirement for kynurenine hydroxilase of rat liver mitochondria. Biochem Biophys Res Commun 29(3):394-399
82. De Castro FT, Price JM, Brown R (1956) Reduced triphosphopyridinenucleotide requirement for the enzymatic formation of 3-hydroxykynurenine from L-kynurenine. J Am Chem Soc 78:2904-2905
83. 2O during hydroxylation of L-[3,5-3H]kynurenine. Anal Biochem 205(2):257-262
84. De Castro FT, Brown RR, Price JM (1957) The intermediary metabolism of tryptophan by cat and rat tissue preparations. J Biol Chem 28:777-784
85. Heyes MP, Saito K, Markey SP (1992) Human macrophages convert L-tryptophan into the neurotoxin quinolinic acid. Biochem J 283:633-635
86. Uemura T, Hirai K (1998) L-kynurenine 3-monooxygenase from mitochondrial outer membrane of pig liver: purification, some properties, and monoclonal antibodies directed to the enzyme. J Biochem 123(2):253-262
87. Guillemin GJ, Smith DG, Smythe GA, Armati PJ, Brew BJ (2003) Expression of the kynurenine pathway enzymes in human microglia and macrophages. Adv Exp Med Biol 527:105-112
88. Breton J, Avanzi N, Magagnin S, Covini N, Magistrelli G, Cozzi L, Isacchi A (2000) Functional characterization and mechanism of action of recombinant human kynurenine 3-hydroxylase. Eur J Biochem 267(4):1092-1099
89. Crozier KR, Moran GR (2007) Heterologous expression and purification of kynurenine-3-monooxygenase from Pseudomonas fluorescens strain 17400. Protein Expr Purif 51(2):324-333
90. Nisimoto Y, Takeuchi F, Shibata Y (1977) Molecular properties of L-kynurenine 3-hydroxylase from rat liver mitochondria. J Biochem 81(5):1413-1425
91. Alberati-Giani D, Cesura AM, Broger C, Warren WD, Rover S, Malherbe P (1997) Cloning and functional expression of human kynurenine 3-monooxygenase. FEBS Lett 410(2-3):407-412
92. Constantino G, Mattoli L, Moroni F, Natalini B, Pellicciari R (1996) kynurenine 3-hydroxylase and its selective inhibitors. In: Filippini GA (ed) Recent advances in tryptophan research. New York, pp 493-497
93. Courtney S, Scheel A (2010) Modulation of the kynurenine pathway for the potential treatment of neurodegenerative diseases. In: Dominguez C (ed) Neurodegenerative Diseases. pp 149-176
94. Amaral M, Levy C, Heyes DJ, Lafite P, Outeiro TF, Giorgini F, Leys D, Scrutton NS (2013) Structural basis of kynurenine 3-monooxygenase inhibition. Nature 496(7445):382-385
95. Palfey B, McDonald C (2010) Control of catalysis in flavin-dependent monooxygenases. Arch Biochem Biophys 493(1):26-36
96. McCulloch M, Mukherjee T, Begley TP, Ealick SE (2010) Structure of the PLP degradative enzyme 2-methyl-3-hydroxypyridine-5-carboxylic acid oxygenase from Mesorhizobium loti MAFF303099 and its mechanistic implications. Biochemistry 48(19):4139-4149